Seek Returns

ABBV vs. PCVX: AbbVie vs. Vaxcyte Stock Comparison

How do AbbVie (ABBV) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for AbbVie (ABBV) and Vaxcyte (PCVX)
Profile ItemABBVPCVX
NameAbbVie Inc.Vaxcyte Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization514.92 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateJanuary 2, 2013June 12, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ABBV
PCVX
GSPC
Loading price history…
AbbVie (ABBV) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for AbbVie (ABBV) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for AbbVie (ABBV) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and Vaxcyte (PCVX)
MetricABBVPCVX
Total Return (1Y)37.33%59.00%
Total Return (3Y, Annualized)32.74%11.29%
Total Return (5Y, Annualized)24.73%21.60%

Risk Profile

Drawdown History

ABBV
PCVX
GSPC
Loading price history…
AbbVie (ABBV) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for AbbVie (ABBV) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AbbVie (ABBV) and Vaxcyte (PCVX)
MetricABBVPCVX
Volatility (1Y, Annualized)25.65%56.01%
Beta (5Y)0.211.26
Max Drawdown (5Y)-21.92%-76.22%
Avg. Volume (3M)4.76M2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ABBV and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and Vaxcyte (PCVX)
MetricABBVPCVX
Sharpe Ratio (1Y)1.290.98
Sortino Ratio (1Y)2.021.76

Profitability

ROE (TTM)

AbbVie (ABBV) has no ROE value reported for this period; Vaxcyte (PCVX) reports a negative figure of -42.68%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
ABBV
--

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): ABBV does not report ROE, so it has no value marker; PCVX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

AbbVie (ABBV) at 15.67% retains a top-quartile share of revenue as profit, ahead of Vaxcyte (PCVX) at 0.00%, which keeps about the industry-typical share.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max
18.05%
ABBV
15.67%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

AbbVie (ABBV) at 39.59% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max
83.12%
ABBV
39.59%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and Vaxcyte (PCVX)
MetricABBVPCVX
ROE (TTM)---42.68%
ROA (TTM)10.74%-24.98%
Net Margin (TTM)15.67%0.00%
Operating Margin (TTM)39.59%0.00%
Gross Margin (TTM)73.72%0.00%

Growth

Revenue Growth

Only one side can be read here: AbbVie (ABBV) reports revenue growth of 8.57%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: AbbVie (ABBV) reports EPS growth of -0.84%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AbbVie (ABBV) and Vaxcyte (PCVX)
MetricABBVPCVX
Revenue Growth (YoY)8.57%--
Revenue Growth (3Y CAGR)1.75%--
EPS Growth (YoY)-0.84%--
EPS Growth (3Y CAGR)-29.03%--

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ABBV.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ABBV
0.87
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Vaxcyte (PCVX) carries debt-to-equity ratio of 0.09 against its industry range, while AbbVie (ABBV) reports no figure this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
ABBV
--

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): ABBV does not report debt-to-equity ratio, so it has no value marker; PCVX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and Vaxcyte (PCVX)
MetricABBVPCVX
Current Ratio (MRQ)0.874.56
Debt / Equity (MRQ)--0.09
Net Debt / EBITDA2.21--

Dividends

Dividend Yield (TTM)

Vaxcyte (PCVX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV
2.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Vaxcyte (PCVX) pays no dividend (payout 0.00%).

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV
117.35%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and Vaxcyte (PCVX)
MetricABBVPCVX
Dividend Yield (TTM)2.40%0.00%
Dividend Payout Ratio (TTM)117.35%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: AbbVie (ABBV) trades at 50.05 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max
85.34
ABBV
50.05
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): PCVX does not report P/E ratio, so it has no value marker; ABBV is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for AbbVie (ABBV), whose P/S ratio of 7.80 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max
58.18
Q3
25.77
ABBV
7.80
Median
7.30
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; ABBV is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Vaxcyte (PCVX) reports 3.83, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
ABBV
-112.34

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
AbbVie (ABBV) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and Vaxcyte (PCVX)
MetricABBVPCVX
P/E Ratio (TTM)50.05--
P/S Ratio (TTM)7.80--
P/B Ratio (MRQ)-112.343.83
Free Cash Flow Yield (TTM)3.44%-5.24%